WO2013172741A2 - Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси) циклогексен-1-карбоновые кислоты, их эфиры и способ применения - Google Patents
Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси) циклогексен-1-карбоновые кислоты, их эфиры и способ применения Download PDFInfo
- Publication number
- WO2013172741A2 WO2013172741A2 PCT/RU2013/000384 RU2013000384W WO2013172741A2 WO 2013172741 A2 WO2013172741 A2 WO 2013172741A2 RU 2013000384 W RU2013000384 W RU 2013000384W WO 2013172741 A2 WO2013172741 A2 WO 2013172741A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yloxy
- pentan
- cyclohexene
- guanidino
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Definitions
- This invention relates to new compounds - fluorine-substituted (3R, 4R, 5S) - 5-guanidino-4-acylamino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acids and their esters - inhibitors of neuraminidase activity.
- neuraminidase are pathogenic to humans and animals, such as birds, horses, pigs, seals. Such pathogens include influenza virus. Neuraminidase is associated with the pathogenicity of the influenza virus.
- the new fluoro-substituted (31, 4K, 58) -5-guanidino-4-acylamino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acids and their esters are of interest as drug substances for the creation of new drugs, intended for the prevention and treatment of influenza.
- Known inhibitors of neuraminidase are (3R, 4R, 5S) -5-amino-3-alkyloxy-4-acetylaminocyclohexene-1-carboxylic acids A1, the most active of which is (3R, 4R, 5S) -5-aMHHO-4 -a4eTKnaMHHo-3- (neHTaH-3-yloxy) cyclohexene-1-carboxylic acid A2, which, as shown by X-ray diffraction data for the acid complex with the influenza virus neuraminidase, effectively binds to the active site of the enzyme (Oseltamivir Carboxylate) [C. U. Kim, W. Lew, M. A. Williams, et al. J. Am. Chem. Soc. 1997, 119, 681-690.].
- Oseltamivir carboxylate A3 ethyl ester known as Oseltamivir phosphate or Tamiflu (Oseltamivir Phosphate, Tamiflu) [J. C. Rohloff, K. M. Kent, M. J. Postich, et al. J. Org. Chem. 1998, 63, 4545.], is the medicinal precursor of oseltamivir carboxylate A2.
- Alkenyl means an aliphatic linear or branched hydrocarbon group containing from 2 to 7 carbon atoms and including at least one carbon-carbon double bond. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
- Preferred alkyl groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, n-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbnylmethyl, benzyloxycarbonylmethylmethyl and pyridinyl.
- Preferred alkenyl groups are ethenyl, propenyl, n-butenyl, isobutenyl, 3-methylbut-2-enyl, n-pentenyl, and cyclohexylbutenyl.
- Alkyl means an aliphatic hydrocarbon linear or branched group with 1-12 carbon atoms in the chain. Branched means that the alkyl chain has one or more "lower alkyl” substituents.
- Alkyl may have one or more identical or different substituents (“alkyl substituents”) including halogen, alkenyloxy, cycloalkyl, aryl, heteroaryl, heterocyclyl, aroyl, cyano, hydroxy, alkoxy, carboxy, alkynyloxy, aralkoxy, aryloxy, aryloxycarbenyl, alkylthio, heteroaryo , aralkylthio, arylsulfonyl, alkylsulfonylheteroaralkyloxy, annelated heteroarylcycloalkenyl, annelated heteroarylcycloalkyl annelated heteroarylheterocyclenyl, annelirovannyi heteroarylhetero
- Preferred alkyl groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, iso-propyl, n-butyl, ret-butyl, n-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonylmethylmethyloxycarbylmethyloxycarbonylmethyloxycarbonylmethyloxycarbonylmethyloxycarbonylmethyloxycarbonymethyloxycarbonylmethyloxycarbonylmethyloxycarbonylmethyloxycarbonylmethyloxycarbonylmethylene .
- Alkynyl means an aliphatic linear or branched hydrocarbon group containing from 2 to 12 carbon atoms and including at least one carbon-carbon triple bond. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl, are attached to the linear alkynyl chain.
- Preferred alkyl the groups are methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbnylmethyl, benzyloxycarbonylmethyl and pyridylmethyloxy.
- Preferred alkynyl groups are ethynyl, propynyl, n-butynyl, isobutynyl, 3-methylbut-2-ynyl, n-pentynyl, buta-1,3-diine and hexa-1,3,5-triine.
- Hydrate means a stoichiometric or non-stoichiometric composition of a compound or its salt with water.
- Medical substance (drug substance, drug substance) means a physiologically active substance of synthetic or other (biotechnological, plant, animal, microbial and other) origin, having pharmacological activity and is the active principle of a pharmaceutical composition used for the manufacture and manufacture of a drug drug (funds).
- Medical product (preparation) a substance (or a mixture of substances in the form of a pharmaceutical composition), in the form of tablets, capsules of injections, ointments, and other finished forms designed to restore, correct, or alter physiological functions in humans and animals, as well as for the treatment and disease prevention, diagnosis, anesthesia, contraception, cosmetology and more.
- Neuraminidase is an enzyme common to animals and a number of microorganisms. It is a glycohydrolase that cleaves alpha-ketosidically linked sialic acids from glycoproteins, glycolipids and oligosaccharides. Many of the microorganisms containing neuraminidase are pathogenic to humans and other animals, including poultry, horses, pigs and seals. Such pathogens include the influenza virus. Neuraminidase is associated with the pathogenicity of the influenza virus. Presumably, it promotes the elution of newly synthesized virions from infected cells and the movement of the virus (due to its hydrolase activity) through the mucus of the respiratory tract.
- “Pharmaceutical composition” means a composition comprising a compound of formula 1 and at least one of the components selected from the group consisting of pharmaceutically acceptable and pharmacologically compatible excipients, solvents, diluents, carriers, excipients, distribution and perceiving means of delivery, such as preservatives, stabilizers, fillers, grinders, moisturizers, emulsifiers, suspending agents, thickeners, sweeteners, perfumes, flavors, antibacterial agents, fungicides, lubricants, prolonged delivery regulators, the choice and ratio of which depends on the nature and method of administration and dosage.
- suspending agents examples include ethoxylated isostearyl alcohol, polyoxyethylene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, as well as mixtures of these substances. Protection against the action of microorganisms can be achieved using a variety of antibacterial and antifungal agents, for example, parabens, chlorobutanol, sorbic acid and the like.
- the composition may also include isotonic agents, for example, sugars, sodium chloride and the like.
- the prolonged action of the composition can be achieved using agents that slow down the absorption of the active principle, for example, aluminum monostearate and gelatin.
- suitable carriers, solvents, diluents and delivery vehicles are water, ethanol, polyalcohols, and also mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).
- excipients are lactose, milk sugar, sodium citrate, calcium carbonate, calcium phosphate and the like.
- grinders and distributors are starch, alginic acid and its salts, silicates.
- lubricants are magnesium stearate, sodium lauryl sulfate, talc, and high molecular weight polyethylene glycol.
- the pharmaceutical composition for oral, sublingual, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of the active principle, alone or in combination with another active principle, can be administered to animals and humans in a standard administration form, in the form of a mixture with traditional pharmaceutical carriers.
- Suitable unit dosage forms include oral forms such as tablets, gelatine capsules, pills, powders, granules, chewing gums and oral solutions or suspensions, sublingual and buccal administration forms, aerosols, implants, local, transdermal, subcutaneous, intramuscular, intravenous, intranasal or intraocular administration forms and rectal administration forms.
- “Pharmaceutically acceptable salt” means the relatively non-toxic organic and inorganic salts of the acids and bases of the present invention.
- salts can be obtained in situ during the synthesis, isolation or purification of the compounds or prepared specially.
- base salts can be prepared specifically based on the purified free base of the claimed compound and a suitable organic or inorganic acid.
- salts thus obtained are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like (Detailed description of the properties of such salts is given in Berge SM, et al., Pharmaceutical Salts J.
- Salts of the claimed acids can also be specially prepared by reacting the purified acid with a suitable base, and metal and amine salts can be synthesized.
- Metal salts include sodium, potassium, calcium, barium, zinc, magnesium, lithium and aluminum salts, the most desirable of which are sodium and potassium salts.
- Suitable inorganic bases from which metal salts can be obtained are hydroxide, carbonate, sodium bicarbonate and hydride, potassium hydroxide and bicarbonate, potash, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide.
- amines and amino acids are selected that are sufficiently basic to form a stable salt and are suitable for medical use (in particular, they should have low toxicity).
- amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris (hydroxymethyl) aminomethane and the like.
- tetraalkylammonium hydroxides for example, such as choline, tetramethylammonium, tetraethylammonium and the like, can be used for salt formation.
- amino acids the main amino acids can be used - lysine, ornithine and arginine.
- neuraminidase inhibitors which are previously unknown previously fluorine-substituted (311.4Rch, 58) -4-acylamino-5-guanidino-3- (pentan-3- yloxy) cyclohexene-1-carboxylic acids and their esters of the general formula, pharmaceutically acceptable salts and / or hydrates.
- R represents hydrogen, optionally substituted C1-C 5 alkyl, C 2 - C 5 alkenyl or C 2 -C 5 alkynyl; Rf represents a CH 2 F or CHF 2 radical.
- compounds of the general formula 1 are preferred in which R is hydrogen, methyl or ethyl.
- more preferred compounds of the general formula 1 are: (W, 41, 58) -5-guanidino-4-fluoroacetylamino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acid 1.1, its methyl ester 1.2 and ethyl 1.3 ether, (ZK, 4K, 58) -5-guanidino-4-difluoroacetylamino-3- (pentan-3-yloxy) cyclohexene-1 carboxylic acid 1.4, its methyl ether 1.5 and ethyl 1.6 ether.
- Influenza virus neuraminidase inhibitors of general formula 1 are prepared starting from alkyl 4-amino-5- (ire / i-butoxycarbonylamino) -3- (pentan-3-yloxy) cyclohexene-1-carboxylate of general formula 2 according to the following scheme.
- New influenza neuraminidase inhibitors which are previously unknown (ZK, 4K, 58) -4- (2-fluoroacetylamino) - and (3R, 4R, 5S) -4- (2,2-difluoroacetylamino) - 5-guanidino-3 - (pentan-3-yloxy) cyclohexen-1-carboxylic acids and their esters of the general formula 1 and their pharmaceutically acceptable salts also showed high influenza activity in animal models of influenza pneumonia.
- Antineuraminidase activity of the compounds was determined according to the method described in [Who Collaborating Center for Reference & Research on Influenza, Australia, Standard Operating Procedure WHO - 025. Reviewed by: Aeron Hurt, Senior Philosoph Review Date: 13/3/2009].
- the new compounds of General formula 1 are a drug source for the preparation of pharmaceutical compositions and formulations for the prevention and treatment of influenza in warm-blooded animals and humans.
- the subject of this invention is a pharmaceutical composition
- a pharmaceutical composition comprising, as a drug principle, the compounds of general formula 1 or their pharmaceutically acceptable salts in a therapeutically effective amount.
- compositions may include pharmaceutically acceptable excipients.
- pharmaceutically acceptable excipients is meant diluents, excipients and / or carriers used in the pharmaceutical field.
- the pharmaceutical composition along with the compound of general formula 1 or a pharmaceutically acceptable salt and / or hydrate thereof of the present invention may include other active substances, including those having anti-influenza activity, provided that they do not cause undesirable effects.
- the use of the pharmaceutical composition of the present invention in clinical practice it can be mixed with traditional pharmaceutical carriers.
- the carriers used in the pharmaceutical compositions of the present invention are carriers that are used in the pharmaceutical industry to obtain common forms, including: in oral forms, binders, lubricants, disintegrants, solvents, diluents, stabilizers, suspending agents, colorless are used agents, flavoring agents of taste; antiseptic agents, solubilizers, stabilizers are used in injection forms; in local forms, bases, diluents, lubricants, antiseptic agents are used.
- the subject of this invention is a method for producing a pharmaceutical composition by mixing with an inert excipient and / or solvent, at least one drug principle (substance) of the general formula 1 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount.
- the subject of this invention is also a medicament having influenza activity, in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, intended for the prophylaxis of treatment of influenza in humans and warm-blooded animals, including an influenza drug principle (substance) of the general formula 1 or a pharmaceutical composition comprising a new drug onset of general formula 1 in a therapeutically effective amount.
- a medicament having influenza activity in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, intended for the prophylaxis of treatment of influenza in humans and warm-blooded animals, including an influenza drug principle (substance) of the general formula 1 or a pharmaceutical composition comprising a new drug onset of general formula 1 in a therapeutically effective amount.
- the subject of the present invention is also therapeutic cocktails for treating influenza, comprising, as one of the components, a new drug or a new pharmaceutical composition containing, as an active component, at least one compound of general formula 1 or a pharmaceutically acceptable salt and / or hydrate thereof.
- a therapeutic cocktail for “treating influenza, along with the medicament of the present invention may include other known drugs for treating influenza, or drugs that enhance the patient’s immune system.
- a method for the prevention and treatment of influenza in animals and humans consists in administering to the patient a new drug, a new pharmaceutical composition or a new therapeutic cocktail.
- Medicines may be administered via an inhaler, orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically).
- the clinical dosage of an agent of general formula 1 in patients can be adjusted depending on the therapeutic efficacy and bioavailability of the active ingredients in the body, their metabolic rate and excretion from the body, as well as on the age, gender and stage of the patient’s disease, with a daily dose in adults usually is 10 ⁇ 500 mg, preferably 50 ⁇ 300 mg. Therefore, when preparing the pharmaceutical composition of the drug of the present invention in the form of dosage units, it is necessary to take into account the above effective dosage, with each dosage unit of the drug containing 10 ⁇ 500 mg of an agent of general formula 1, preferably 50 ⁇ 300 mg. As directed by your doctor or to a pharmacist, these drugs can be taken several times during certain periods of time (preferably one to six times).
- the subject of this invention is also a method of inhibiting the activity of neuraminidase in vivo, including influenza neuraminidase, comprising the step of contacting a compound of general formula 1 and a neuraminidase.
- Example 1 Obtaining (GL, 4 g, 55) -ethyl 4- (2,2-difluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-mesylate arboxylate 1.6 * ⁇ 80 ⁇ .
- the resulting 4b product (2.15 g, 0.0048 mol) was dissolved in 20 ml of a 10% solution of trifluoroacetic acid in methylene chloride and stirred at room temperature for 12 hours. Then the solvents were distilled off in vacuo, the remaining oil was dissolved in ethyl acetate, washed with 5% NaHC0 3 solution, dried over Na 2 S0 4 , filtered and dried in vacuum. The product yield is 96% (1.605 g). Additional purification is carried out by column chromatography - eluent is ethyl acetate THF or by recrystallization from hexane.
- Example 2 (H, 41., 55) -ethyl 4- (2-fluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylate mesylate L3-CH3BOZH is prepared according to the procedure described in the example 1 using monofluoroacetic acid as an acylating agent.
- LCMS (M + H): Found 373; Calculated 372.44.
- Example 3 (GL, 4?, 55) -4- (2,2-difluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acid 1.4.
- To a solution of 250 mg (ZL, 4L, 55-ethyl 5- ((2) -2,3-bis (otter »7-butoxycarbonyl) guanidino) -4- (2,2-difluoroacetamido) -3- (pentan-3 - yloxy) cyclohexene-1-carboxylate 6b in 5 ml of dioxane add 2.5 ml of a 5% solution lithium hydroxide and stirred the reaction mass at room temperature for 45 minutes.
- lithium hydroxide is passivated by adding 300 ⁇ l of acetic acid, the solvents are distilled off in vacuo. The resulting precipitate was extracted with isopropyl alcohol, the extract was dried over Na 2 S0 4 and in vacuo. 200 mg (84%) (3L, 4 / g, 55) -5 - ((2) -2,3-bis (t / 7eot-butoxycarbonyl) guanidino) -4- (2,2-difluoroacetamido) -3 are obtained - (pentan-3-yloxy) cyclohexen-1-carboxylic acid 8b.
- Example 5 (3 / ?, 4, 55) -Metyl 4- (2-fluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylate mesylate 1.2-CHjSC H was obtained by the method, described in example 1 using as starting (3 / ?, 4L, 55) -methyl 4-amino-5- (t /> e / and-butoxycarbonylamino) -3- (pentan-3-yloxy) cyclohexene-1- carboxylate and monofluoroacetic acid as an acylating agent.
- Example 6 (3?, 4 / g, 55) -Metyl 4- (2,2-difluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylate mesylate 1.5 'CH.sub.3SO.sub.2 was obtained by the procedure described in example 1 using as the source (GL, 4 /., 55) -methyl 4-amino-5 - (/ ipre-butoxycarbonylamino) -3- (pentan-3-yloxy) cyclohexene-1-carboxylate and difluoroacetic acid as an acylating agent.
- LCMS (M + H): Found 373; Calculated 372.44.
- Example 7 Obtaining a pharmaceutical composition in the form of tablets.
- 1600 mg of starch, 1600 mg of ground lactose, 400 mg of talc and 1000 mg (3 / g, 4 / g, 55) -4- (2-fluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene are mixed -1-carboxylic acid 1.1.
- the resulting bar is crushed into granules and sieved through sieves, collecting granules with a size of 14-16 mesh.
- the granules obtained are tabletted into a suitable tablet form weighing 560 mg each.
- Example 8 Obtaining a pharmaceutical composition in the form of capsules. Thoroughly mix (3 / ?, 4 / ?, 55) -4- (2-fluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acid 1.1 with lactose powder in a 2: 1 ratio The resulting powdery mixture is packaged in 300 mg in a suitable size gelatin capsule.
- Example 9 Obtaining a pharmaceutical composition for intramuscular, intraperitoneal or subcutaneous injection.
- 500 mg of (3R, 4R, 5Si) -4- (2-fluoroacetamido) -5-guanidino-3- (pentan-3-yloxy) cyclohexene-1-carboxylic acid 1.1 are mixed with 300 mg of chlorobutanol, 2 ml of propylene glycol and 100 ml injection water. The resulting solution is filtered and placed in 1 ml ampoules, which are sealed.
- Example 10 Determination of the activity of compounds of General formula 1 in relation to neuraminidase of influenza viruses.
- working dilutions were determined for the allantoic influenza virus strains A / California / 07/09 (H1N1) and A / Aichi / 2/69 (H3N2), as well as for the resistant A / Vladivostok / 16 influenza virus obtained in the cell culture. / 09 (H1N1).
- 60 ⁇ l of each two-fold diluted virus was prepared in the reaction buffer mixture (RBS, 50 mM MES, 5 mM CaCl 2 , pH 6.5) in a 96-well round-bottom plate.
- antineuraminidase activity of the compounds 50 ⁇ l dilutions of compounds of the general formula 1 and analogues of the formula were added to RBS in the 96-well flat bottom plates for measuring fluorescence (FluoroNunc, black, Cat. No. 237105) in order to determine the antineuraminidase activity of the compounds A2 and formulas A4 (concentration 0.03; 0.3; 3; 30; 300; 3000; 30,000 nm - each concentration per row).
- wells of row A were used, to which 50 ⁇ l of RBS was added.
- 50 ⁇ l of the selected working dilutions of each virus on RBS was added to the corresponding wells.
- Example 11 The study of the influenza activity of the compounds of General formula 1 (1.1, 1.Z., 1.4 and 1.6) on the model of influenza pneumonia in mice.
- Pre-weighed mice non-linear females, average weight 12-15 g
- the influenza virus A / Aichi / 2/69 (H3N2) (10 LD 50 in 50 ⁇ l).
- LD 50 was determined by titration of the allantoic virus in the same mice, which were then used in the main experiment.
- the following treatment regimen for the compounds was used: 24 hours before infection, 1 hour before infection, after 24 hours and then 1 time per day for 5 days.
- a single-use insulin syringe with a special needle was used, the effect of the following doses was studied: 25 mg / kg / day of compounds in a volume of 100 ⁇ l.
- Tamiflu was used in doses from 5 mg / kg / day to 30 mg / kg / day.
- the groups “treated with compounds” of general formula 1 and Tamiflu of formula A3 there were 10 mice each. The treated and control animals were monitored daily; in the first 5 days after infection, mice were weighed every day, then every other day.
- the chemotherapeutic activity of the compounds in a mouse influenza pneumonia model was evaluated by the protection against fatal viral infection and weight loss in groups of animals treated with the drug compared to the control group. The decrease or increase in weight was calculated separately for each mouse and expressed as a percentage. Moreover, the weight of the animal before infection was taken as 100%. For all mice of the same group, the average percentage loss or weight gain was determined.
- the dose of the virus is determined containing 10 LD 50 in a volume of 100 ⁇ l. All animals in the experiment are infected with this dose of the virus.
- the efficacy of the compounds of general formula 1 in the mouse influenza pneumonia model was evaluated by the number of animals surviving after virus infection, average life expectancy and weight change of infected animals.
- the anti-influenza efficacy of the studied drugs of general formula 1 and Tamiflu of formula A3 is expressed in a decrease in the rate of weight loss in the treated mice groups compared to the “virus control” group.
- Animal weight loss is one of the clinical signs of the manifestation of influenza pneumonia. A greater decrease in animal weight indicates a more severe course of the disease. Mice were weighed at 1, 2, 3, 4, 5 days after infection, and then every other day until 15 days observations. It was found that in the viral control group, animals lost the most weight 5 days after infection (about 10%). In contrast to viral control, in the groups of animals undergoing treatment with all of these compounds of the general formula 1 and Tamiflu, on average, weight loss was not observed. Starting from day 9, all animals in the groups "treated with compounds" actively and stably gained weight.
- the invention can be used in medicine and veterinary medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014028362-1A BR112014028362B1 (pt) | 2012-05-12 | 2013-05-07 | Ácidos (3r, 4r, 5s)-5-guanidino-4-acetamido-3-(pentan-3-iloxi)cicloexeno-1-carboxílicos flúor substituídos, os seus ésteres, composição farmacêutica e uso da mesma |
MX2014013761A MX360369B (es) | 2012-05-12 | 2013-05-07 | Acidos (3r,4r,5s)-5-guanidino-4-acetamido-3-(pentan-3-iloxi)cicloh exen-1-carboxilicos fluorosustituidos, sus esteres y uso de los mismos. |
CN201380024800.0A CN104284884B (zh) | 2012-05-12 | 2013-05-07 | 氟取代的(3r,4r,5s)-5-胍基-4-乙酰氨基-3-(戊烷-3-基氧基)环己烯-1-甲酸、它们的酯及它们的应用 |
EA201401238A EA024765B1 (ru) | 2012-05-12 | 2013-05-07 | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси)циклогексен-1-карбоновые кислоты, их эфиры и способ применения |
JP2015512601A JP6034960B2 (ja) | 2012-05-12 | 2013-05-07 | フッ素置換(3r、4r、5s)−5−グアニジノ−4−アセトアミド−3−(ペンタン−3−イルオキシ)シクロヘキセン−1−カルボン酸、そのエステル及びその使用 |
EP13791641.7A EP2848606B1 (en) | 2012-05-12 | 2013-05-07 | Fluoro-substituted (3r, 4r, 5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy) cyclohexene-1-carboxylic acids, esters thereof and a method for the use thereof |
DK13791641.7T DK2848606T3 (en) | 2012-05-12 | 2013-05-07 | FLUORO-SUBSTITUTED (3R, 4R, 5S) -5-GUANIDINO-4-ACYLAMINO-3- (PENTAN-3-YLOXY) CYCLOHEXEN-1-CARBOXYLIC ACIDS, ESTERS THEREOF AND A PROCEDURE FOR USE THEREOF |
KR1020147034876A KR101902567B1 (ko) | 2012-05-12 | 2013-05-07 | 플루오로치환된 (3r,4r,5s)-5-구아니디노-4-아세트아미도-3-(펜탄-3-일옥시)사이클로헥센-1-카복실릭 엑시드, 이의 에스테르 및 이의 용도 |
PL13791641T PL2848606T3 (pl) | 2012-05-12 | 2013-05-07 | Fluoropodstawione kwasy (3R, 4R, 5S)-5-guanidyno-4-acyloamino-3-(pentan-3- yloksy)cyklohekseno-1-karboksylowe, ich estry i sposób ich stosowania |
AU2013263513A AU2013263513B2 (en) | 2012-05-12 | 2013-05-07 | Fluoro-substituted (3R, 4R, 5S)-5-guanidino-4-acylamino-3-(pentan-3-yloxy) cyclohexene-1-carboxylic acids, esters thereof and a method for the use thereof |
CA2872733A CA2872733C (en) | 2012-05-12 | 2013-05-07 | Fluorosubstituted (3r,4r,5s)-5-guanidino-4-acetamido-3-(pentan-3-yloxy)cyclohexene-1-carboxylic acids, their esters and use thereof |
UAA201410979A UA113201C2 (xx) | 2012-05-12 | 2013-07-05 | Фторзамісні (3r,4r,5s)-5-гуанідино-4-фторациламіно-3-(пентан-3-ілокси)циклогексен-1-карбонові кислоти, їх ефіри і спосіб застосування |
ZA2014/08026A ZA201408026B (en) | 2012-05-12 | 2014-11-03 | Flouro-substituted (3r,2r,5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy)cyclohexene-1-carbixylic acids, esters thereof and method for the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012119272 | 2012-05-12 | ||
RU2012119272/04A RU2489422C1 (ru) | 2012-05-12 | 2012-05-12 | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси)циклогексен-1-карбоновые кислоты, их эфиры и способ применения |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013172741A2 true WO2013172741A2 (ru) | 2013-11-21 |
WO2013172741A3 WO2013172741A3 (ru) | 2014-01-09 |
Family
ID=49159508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2013/000384 WO2013172741A2 (ru) | 2012-05-12 | 2013-05-07 | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси) циклогексен-1-карбоновые кислоты, их эфиры и способ применения |
Country Status (17)
Country | Link |
---|---|
US (1) | US8895613B2 (ru) |
EP (1) | EP2848606B1 (ru) |
JP (1) | JP6034960B2 (ru) |
KR (1) | KR101902567B1 (ru) |
CN (1) | CN104284884B (ru) |
AU (1) | AU2013263513B2 (ru) |
BR (1) | BR112014028362B1 (ru) |
CA (1) | CA2872733C (ru) |
DK (1) | DK2848606T3 (ru) |
EA (1) | EA024765B1 (ru) |
HU (1) | HUE035856T2 (ru) |
MX (1) | MX360369B (ru) |
PL (1) | PL2848606T3 (ru) |
RU (1) | RU2489422C1 (ru) |
UA (1) | UA113201C2 (ru) |
WO (1) | WO2013172741A2 (ru) |
ZA (1) | ZA201408026B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923060A (zh) * | 2014-03-27 | 2014-07-16 | 山东大学 | 奥司他韦衍生物及其制备方法和应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905193B (zh) * | 2017-02-15 | 2018-11-27 | 中国药科大学 | 芳酰基胍基奥司他韦羧酸衍生物及其制备方法和应用 |
US20190081317A1 (en) * | 2017-09-11 | 2019-03-14 | Andreas Keil | Web coating and calendering system and method |
CN110272381A (zh) * | 2019-06-19 | 2019-09-24 | 五邑大学 | 含吡啶片段的奥司他韦类似物及其应用 |
WO2022022448A1 (zh) * | 2020-07-29 | 2022-02-03 | 广州市恒诺康医药科技有限公司 | 神经氨酸酶抑制剂类化合物、其药物组合物及其用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM354694A0 (en) * | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
SI9620042A (sl) * | 1995-02-27 | 1998-12-31 | Gilead Sciences, Inc. | Novi selektivni inhibitorji virusnih ali bakterijskih neuraminidaz |
JP3233392B2 (ja) * | 1998-01-22 | 2001-11-26 | 三共株式会社 | ノイラミン酸誘導体を含有する抗インフルエンザ薬 |
US6518048B2 (en) * | 2000-04-10 | 2003-02-11 | Hoffmann-La Roche Inc. | Stereo-specific synthesis of shimikic acid derivatives with improved efficiency |
EP2276479B1 (en) * | 2008-04-15 | 2014-07-02 | SineVir Therapeutics LLC | Prodrugs of neuraminidase inhibitors |
RU2469020C1 (ru) * | 2011-11-08 | 2012-12-10 | Александр Васильевич Иващенко | (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения |
-
2012
- 2012-05-12 RU RU2012119272/04A patent/RU2489422C1/ru active
-
2013
- 2013-04-29 US US13/872,174 patent/US8895613B2/en active Active
- 2013-05-07 MX MX2014013761A patent/MX360369B/es active IP Right Grant
- 2013-05-07 AU AU2013263513A patent/AU2013263513B2/en not_active Ceased
- 2013-05-07 DK DK13791641.7T patent/DK2848606T3/en active
- 2013-05-07 EA EA201401238A patent/EA024765B1/ru not_active IP Right Cessation
- 2013-05-07 BR BR112014028362-1A patent/BR112014028362B1/pt active IP Right Grant
- 2013-05-07 HU HUE13791641A patent/HUE035856T2/hu unknown
- 2013-05-07 CA CA2872733A patent/CA2872733C/en not_active Expired - Fee Related
- 2013-05-07 CN CN201380024800.0A patent/CN104284884B/zh active Active
- 2013-05-07 JP JP2015512601A patent/JP6034960B2/ja active Active
- 2013-05-07 EP EP13791641.7A patent/EP2848606B1/en not_active Not-in-force
- 2013-05-07 WO PCT/RU2013/000384 patent/WO2013172741A2/ru active Application Filing
- 2013-05-07 KR KR1020147034876A patent/KR101902567B1/ko active IP Right Grant
- 2013-05-07 PL PL13791641T patent/PL2848606T3/pl unknown
- 2013-07-05 UA UAA201410979A patent/UA113201C2/uk unknown
-
2014
- 2014-11-03 ZA ZA2014/08026A patent/ZA201408026B/en unknown
Non-Patent Citations (6)
Title |
---|
BERGE S.M. ET AL.: "Pharmaceutical Salts", J.PHARM.SCI., vol. 66, 1977, pages 1 - 19 |
C. U. KIM; W. LEW; M. A. WILLIAMS ET AL., J. AM. CHEM. SOC., vol. 119, 1997, pages 681 - 690 |
J. C. ROHLOFF; K. M. KENT; M. J. POSTICH ET AL., J. ORG. CHEM., vol. 63, 1998, pages 4545 |
J. M. WOODS; R. C. BETHELL; J. A. COATES ET AL.: "4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro", ANTIMICROB AGENTS CHEMOTHER, vol. 37, no. 7, 1993, pages 1473 - 1479 |
Q.-S. DU; R.-B. HUANG; Y.-T. WEI; Z.-W. PA; L.-Q. DU; K.-C. CHOU: "Fragment-Based Quantitative Structure-Activity Relationship (FB-QSAR) for Fragment-Based Drug Design", J. COMPUT. CHEM., vol. 30, no. 2, 2008, pages 295 - 304 |
See also references of EP2848606A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923060A (zh) * | 2014-03-27 | 2014-07-16 | 山东大学 | 奥司他韦衍生物及其制备方法和应用 |
CN103923060B (zh) * | 2014-03-27 | 2016-05-25 | 山东大学 | 奥司他韦衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
DK2848606T3 (en) | 2017-10-02 |
EA024765B1 (ru) | 2016-10-31 |
RU2489422C1 (ru) | 2013-08-10 |
US20130303609A1 (en) | 2013-11-14 |
EP2848606B1 (en) | 2017-08-30 |
ZA201408026B (en) | 2015-11-25 |
US8895613B2 (en) | 2014-11-25 |
EP2848606A4 (en) | 2015-12-23 |
PL2848606T3 (pl) | 2018-01-31 |
BR112014028362B1 (pt) | 2022-02-01 |
CN104284884A (zh) | 2015-01-14 |
MX2014013761A (es) | 2015-02-04 |
CA2872733C (en) | 2017-03-21 |
WO2013172741A3 (ru) | 2014-01-09 |
UA113201C2 (xx) | 2016-12-26 |
EA201401238A1 (ru) | 2015-02-27 |
CN104284884B (zh) | 2016-07-13 |
AU2013263513A1 (en) | 2014-11-06 |
JP6034960B2 (ja) | 2016-11-30 |
MX360369B (es) | 2018-10-29 |
JP2015521186A (ja) | 2015-07-27 |
AU2013263513B2 (en) | 2016-10-06 |
EP2848606A2 (en) | 2015-03-18 |
BR112014028362A2 (pt) | 2018-04-17 |
KR20150017734A (ko) | 2015-02-17 |
KR101902567B1 (ko) | 2018-09-28 |
HUE035856T2 (hu) | 2018-05-28 |
CA2872733A1 (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9771361B2 (en) | Inhibitors of influenza viruses replication | |
JP5509080B2 (ja) | 抗インフルエンザ活性を有するオセルタミビル含有ホスホネートコンジナーの合成 | |
WO1999033781A1 (en) | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors | |
RU2489422C1 (ru) | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси)циклогексен-1-карбоновые кислоты, их эфиры и способ применения | |
KR101422744B1 (ko) | (1s,2s,3s,4r)-3-[(1s)-1-아세틸아미노-2-에틸-부틸]-4-구아니디노-2-하이드록시-사이클로펜틸―1-카복실산 하이드레이트 및 이의 약제학적 용도 | |
EP0933993A1 (en) | Substituted cyclopentane compounds useful as neuraminidase inhibitors | |
RU2469020C1 (ru) | (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения | |
WO2016007046A1 (ru) | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты | |
EP3294735B1 (en) | Inhibitors of influenza viruses replication | |
JP2022500375A (ja) | ピリドピラジン系及びピリドトリアジン系インフルエンザウィルス複製阻害剤 | |
CN112771048B (zh) | 流感病毒复制抑制剂及其中间体和用途 | |
CN110240624B (zh) | 一种雄甾烷衍生物及其制备方法与应用 | |
CN114502150B (zh) | 一种用于治疗病毒性感冒的药物组合物及其制剂 | |
RU2520836C1 (ru) | (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения | |
CN113116899A (zh) | 一种用于治疗流感的药物组合物及含有该药物组合物的制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: A201410979 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2872733 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013263513 Country of ref document: AU Date of ref document: 20130507 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/013761 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2015512601 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014/16289 Country of ref document: TR |
|
REEP | Request for entry into the european phase |
Ref document number: 2013791641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013791641 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201401238 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20147034876 Country of ref document: KR Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13791641 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014028362 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014028362 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141112 |